Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2025 17:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna Announces Results of Annual Meeting of Shareholders

Medicenna Announces Results of Annual Meeting of Shareholders
September 19, 2025 07:45 ET | Source: Alvotech

Markaðsleyfi veitt í Japan fyrir þrjár nýjar líftæknilyfjahliðstæður frá Alvotech

REYKJAVÍK 19. september 2025 - Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að japanska heilbrigðis-, atvinnu- og velferðarráðuneytið hafi veitt Fuji Pharma Co. Ltd. („Fuji Pharma“),...
September 19, 2025 07:45 ET | Source: Alvotech

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...
September 05, 2025 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Medicenna will present and participate in one-on-one meetings at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.
September 04, 2025 09:15 ET | Source: Alvotech

Alvotech tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley í New York

Alvotech (NASDAQ: ALVO) tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley, sem haldin verður dagana 8.-10. september nk., í New York. Fundir með fjárfestum verða haldnir...
September 04, 2025 09:15 ET | Source: Alvotech

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its...
August 21, 2025 04:30 ET | Source: Alvotech

Alvotech hlýtur leyfi til markaðssetningar í Evrópu á hliðstæðu við augnlyfið Eylea

Lyfið verður markaðssett í Evrópu undir heitinu Mynzepli og verður notað til meðferðar við augnbotnahrörnun og fleiri augnsjúkdómumMilljónir Evrópubúa þurfa að takast á við áhrif...
August 21, 2025 04:30 ET | Source: Alvotech

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration...
August 20, 2025 06:05 ET | Source: Alvotech

Alvotech utser Patrik Ling till VP of Investor Relations Scandinavia

REYKJAVIK, ISLAND (20 augusti 2025) — Alvotech (NASDAQ: ALVO), ett globalt bioteknikföretag som specialiserat sig på utveckling och tillverkning av biosimilarer för patienter över hela världen,...
August 20, 2025 06:05 ET | Source: Alvotech

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced...